Merck Gets European OK for Keytruda in Triple-Negative Breast Cancer
22 Outubro 2021 - 8:36AM
Dow Jones News
By Colin Kellaher
Merck & Co. on Friday said the European Commission approved
expanded use of its blockbuster cancer drug Keytruda in combination
with chemotherapy for the first-line treatment of certain patients
with locally recurrent unresectable or metastatic triple-negative
breast cancer.
The Kenilworth, N.J., drugmaker said the approval, its first for
Keytruda in Europe in a breast-cancer setting, covers the treatment
of adults whose tumors express PD-L1 with a combined positive score
of at least 10 and who haven't received prior chemotherapy for
metastatic disease.
Keytruda, a cancer drug that harnesses a patient's immune system
to fight tumors, is approved in numerous indications across a range
of cancers around the world.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 22, 2021 07:21 ET (11:21 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Merck (NYSE:MRK)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
